Moderna has recently made headlines by withdrawing its application for the combined COVID-19 and influenza vaccine from the FDA. This comes as the company plans to resubmit the application with updated efficacy data, following a trial that showed promising results for a dual shot. While initial studies suggested that the combination vaccine could be as effective as individual vaccines for older adults, experts warn that approval may face delays. The latest developments raise questions about the future of mRNA-1083, sparking discussions about the ongoing need for innovation in vaccine technology as the workforce seeks support and purpose.